Skip to main content

Milestone 2.L

ADRD Specific Milestone

Advance basic and clinical research on common mechanisms of multi-etiology cognitive impairment and dementia.


Success Criteria

  • Initiate at least one new funding opportunity announcement that promotes understanding of interactions among different pathologies of dementia, e.g. beta-amyloidosis, 3R/4R tauopathy, 4R tauopathy, TDP-43, alpha-synucleinopathy, arteriolosclerosis and other cerebrovascular diseases, as well as other neurodegenerative processes such as TBI or prion diseases.
  • Support research in general and diverse U.S. populations focused on identifying molecular pathways that, during aging, either accelerate cognitive decline or protect against cognitive decline and non-cognitive but related symptoms such as gait impairment or physical frailty. This research should be designed to further develop and optimize biomarkers of age-related cognitive impairment and dementia for clinical trials, clinical research, and toward general clinical use.
  • Develop research nomenclature for dementia that can clearly and accurately communicate the emerging scientific understanding of multiple etiology dementias both in research and in clinical practice.


Research Implementation Area
AD Related Dementias - Specific
Timeline
2016–2023
Status
In Progress

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations